Abstract
to assess/correlate health-related quality of life with the social dimension of hematopoietic, autologous and allogeneic stem cell transplant patients in the three years post-transplant. longitudinal, observational study with 55 patients, in a reference hospital in Latin America, from September 2013 to February 2019, using the Quality of Life Questionnaire-Core and Functional Assessment Cancer Therapy Bone Marrow Transplantation. A total of 71% underwent allogeneic transplantation. The social dimension had low averages since the baseline stage (55, 21) and low scores (56) for quality of life in pancytopenia. There was a significant positive correlation between social dimension, quality of life in pancytopenia (p<0.01) and follow-up after hospital discharge (p<0.00). There is a significant difference (p<0.00) throughout the stages, however, not in terms of the type of transplant (p>0.36/0.86). patients with better assessments in the social dimension have a better quality of life. Interventions focusing on the multidimensionality of the quality of life construct are necessary.
Highlights
METHODSHematological cancer, among which leukemias and lymphomas are included, has become common worldwide
Among the therapeutic options for hematological cancer patients is the Hematopoietic Stem Cell Transplantation (HSCT), which can be of the autologous type, when the cells come from the patient him/herself, or allogeneic, when they come from another individual, being a relative or not
36 (92.32%) of those who had allogeneic HSCT were diagnosed with some type of leukemia
Summary
Hematological cancer, among which leukemias and lymphomas are included, has become common worldwide. According to the International Agency for Research on Cancer (IARC), the number of new cases of leukemia and lymphoma in 2018 was nearly 437 thousand and 589 thousand, respectively. For the year 2040, this estimate will increase to more than 656 thousand new cases for leukemia and 918 thousand for lymphoma[1]. In Brazil, according to the Instituto Nacional do Câncer José Alencar Gomes da Silva (INCA) (National Cancer Institute José Alencar Gomes da Silva), for the period 2020-2022, it is estimated that 10,810 and 14,670 new cases of leukemia and lymphoma will occur, respectively[2]. The choice of the origin of the cells and their modality depend on the disease, the patient’s clinical conditions and the availability of donors[3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
